Amarin Corp Plcuk (AMRN) Operating Expenses (2010 - 2026)
Amarin Corp Plcuk (AMRN) reported Operating Expenses of $29.1 million for Q1 2026, down 30.52% year-over-year from $41.9 million in Q1 2025, and down 1.33% quarter-over-quarter from $29.5 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Operating Expenses (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 17 years of Operating Expenses data on file, last reported at $29.1 million in Q1 2026.
- Operating Expenses for Q1 2026 came in at $29.1 million, down 30.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $158.3 million (down 6.68% YoY), and the FY2025 annual result was $171.0 million, down 1.24% from the prior year.
- Operating Expenses fell to $29.1 million in Q1 2026 per AMRN's latest filing, from $29.5 million in the prior quarter.
- Over five years, Operating Expenses peaked at $106.5 million in Q2 2022 and troughed at $29.1 million in Q1 2026.
- A 5-year average of $56.2 million and a median of $50.0 million in 2023 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2022 and 2025: Operating Expenses sank 45.55% in 2022, then jumped 53.25% in 2025.
- A 5-year view of Operating Expenses shows it stood at $73.2 million in 2022, then slumped by 31.74% to $50.0 million in 2023, then retreated by 14.02% to $43.0 million in 2024, then tumbled by 31.34% to $29.5 million in 2025, then fell by 1.33% to $29.1 million in 2026.
- Business Quant data shows AMRN's Operating Expenses at $29.1 million in Q1 2026, $29.5 million in Q4 2025, and $33.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | -5.14 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 6.72 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 9.59 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 11.01 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 19.82 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 5.95 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 4.37 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 5.50 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 8.25 Bn |
| 10 | Amarin Corp Plcuk | 6.77 Bn | 6.59 Bn | 17.77 Mn | 29.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29.10 Mn |
| Dec 31, 2025 | 29.49 Mn |
| Sep 30, 2025 | 33.31 Mn |
| Jun 30, 2025 | 66.35 Mn |
| Mar 31, 2025 | 41.89 Mn |
| Dec 31, 2024 | 42.96 Mn |
| Sep 30, 2024 | 41.44 Mn |
| Jun 30, 2024 | 43.29 Mn |
| Mar 31, 2024 | 45.49 Mn |
| Dec 31, 2023 | 49.96 Mn |
| Sep 30, 2023 | 51.27 Mn |
| Jun 30, 2023 | 66.63 Mn |
| Mar 31, 2023 | 65.27 Mn |
| Dec 31, 2022 | 73.19 Mn |
| Sep 30, 2022 | 68.00 Mn |
| Jun 30, 2022 | 106.46 Mn |
| Mar 31, 2022 | 100.70 Mn |
| Dec 31, 2021 | 97.72 Mn |
| Sep 30, 2021 | 124.90 Mn |
| Jun 30, 2021 | 113.56 Mn |